Basic Research

Molecular mechanism of Mettl14 mediated m6A modification in improving myocardial infarction

  • Xuebin ZHENG ,
  • Sha SHA ,
  • Huiqiong YANG ,
  • Lian LIU
Expand
  • Department of General Practice,Changsha Fourth Hospital (Changsha Hospital Affiliated to Hunan Normal University),Changsha 410006,China

Received date: 2023-05-14

  Online published: 2023-12-19

Abstract

Objective To investigate the biological role of methyltransferase-like 14 (METTL14)-mediated m6A modification in myocardial infarction (MI). Methods A total of 40 mice were randomly divided into 4 groups: Sham+AAV9-NC group (n = 10), Sham+AAV9-METTL14 group (n = 10), MI+AAV9-NC group (n = 10) and MI+AAV9-METTL14 group (n = 10). Mice in each group were injected with AAV9-METTL14 or AAV9-NC through the tail vein one week before MI induction. Cardiac function was measured non-invasively by transthoracic echocardiography, and microvascular injury were measured by immunofluorescence. CMECs were isolated from mouse myocardial tissue, and the cells were treated with oxygen-glucose deprivation (OGD). Results METTL14 was downregulated in MI mouse heart tissue as well as in OGD-treated CMECs. Compared with the Sham+AAV9-NC group, the expression of VE-cadherin was significantly down-regulated (P < 0.05), ROS levels increased significantly (P < 0.05) in the MI+AAV9-NC group. MI+AAV9-METTL14 suppressed these changes and enhanced cardiac function in mice. Compared with the NC group, a significant increase in mitochondrial ROS levels was observed in the OGD group (P < 0.05). Knockdown of METTL14 in CMECs exacerbated ROS levels (P < 0.05), and the addition of USP48 overexpression plasmid reversed these changes (P < 0.05). Conclusion METTL14 was lowly expressed in MI and mediates mitochondrial dysfunction in CMECs by increasing the m6A modification level of USP48 in CMECs to reduce its stability.

Cite this article

Xuebin ZHENG , Sha SHA , Huiqiong YANG , Lian LIU . Molecular mechanism of Mettl14 mediated m6A modification in improving myocardial infarction[J]. The Journal of Practical Medicine, 2023 , 39(21) : 2754 -2760 . DOI: 10.3969/j.issn.1006-5725.2023.21.011

References

1 王天杰, 董军乐, 王妍, 等. 急性ST段抬高型心肌梗死合并慢性闭塞病变的近远期预后分析[J]. 中华心血管病杂志, 2021, 49(6): 580-585.
2 张师儒, 李瑞雪, 焦云娣, 等. 梗死面积对急性ST段抬高型心肌梗死患者预后的预测价值[J]. 中华内科杂志, 2021, 60(8): 751-756.
3 邱依聆, 陈乐, 江燕萍. 重金属暴露影响DNA甲基化并导致先天性心脏病发生的研究进展[J]. 实用医学杂志, 2021, 37(5): 692-695.
4 WU S, ZHANG S, WU X, et al. m6A RNA methylation in cardiovascular diseases[J]. Mol Ther, 2020, 28(10): 2111-2119.
5 PARAMASIVAM A, VIJAYASHREE PRIYADHARSINI J, RAGHUNANDHAKUMAR S. N6-adenosine methylation (m6A): a promising new molecular target in hypertension and cardiovascular diseases[J]. Hypertens Res, 2020, 43(2): 153-154.
6 MENG L, LIN H, HUANG X, et al. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA[J]. Cell Death Dis, 2022, 13(1): 38.
7 MARUYAMA K, NAEMURA K, YOSHIHARA K, et al. Surgical protocol for permanent ligation of the left anterior descending coronary artery in mice to generate a model of myocardial infarction[J]. STAR Protoc, 2021, 2(3): 100775.
8 LI S, CHEN J, LIU M, et al. Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia-reperfusion injury[J]. Basic Res Cardiol, 2021, 116(1): 65.
9 CROOKS D R, MAIO N, LANG M, et al. Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer[J]. Sci Signal, 2021, 14(664): eabc4436.
10 韩娟娟, 张新安, 艾福录. m6A RNA甲基化修饰异常在肿瘤中的作用[J]. 中国生物化学与分子生物学报, 2020, 36(4): 383-391.
11 WANG X, FENG J, XUE Y, et al. Structural basis of N6-adenosine methylation by the METTL3-METTL14 complex[J]. Nature, 2016, 534(7608): 575-578.
12 ZHANG B, JIANG H, DONG Z, et al. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases[J]. Genes Dis, 2021, 8(6): 746-758.
13 ZHANG R, QU Y, JI Z, et al. METTL3 mediates Ang-II-induced cardiac hypertrophy through accelerating pri-miR-221/222 maturation in an m6A-dependent manner[J]. Cell Mol Biol Lett, 2022, 27(1): 55.
14 ZHAO K, YANG C, ZHANG J, et al. METTL14improves cardiomyocyte proliferation upon myocardial infarction via upregulating miR-17-3p in a DGCR8-dependent manner[J]. Cell Death Discov, 2021, 7(1): 291.
15 LI T, ZHUANG Y, YANG W, et al. Silencing ofMETTL14attenuates cardiac fibrosis induced by myocardial infarction via inhibiting the activation of cardiac fibroblasts[J]. FASEB J, 2021, 35(2): e21162.
16 CHEN J, NING Y, ZHANG H, et al. METTL14-dependent m6A regulates vascular calcification induced by indoxyl sulfate[J]. Life Sci, 2019, 239: 117034.
17 JIAN D, WANG Y, JIAN L, et al. METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications[J]. Theranostics, 2020, 10(20): 8939-8956.
18 PANG P, QU Z, YU S, et al. Mettl14 attenuates cardiac ischemia/reperfusion injury by regulating wnt1/β-catenin signaling pathway[J]. Front Cell Dev Biol, 2021, 9: 762853.
19 AGHAJANI NARGESI A, ZHU X Y, ZHANG L, et al. Renovascular Hypertension Induces Myocardial Mitochondrial Damage, Contributing to Cardiac Injury and Dysfunction in Pigs With Metabolic Syndrome[J]. Am J Hypertens, 2019, 34(2): 172-182.
20 ZHANG Y, WANG Y, XU J, et al. Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways[J]. J Pineal Res, 2019, 66(2): e12542.
21 DU L, LI Y, KANG M, et al. USP48 is upregulated by Mettl14 to attenuate hepatocellular carcinoma via regulating SIRT6 stabilization[J]. Cancer Res, 2021, 81(14): 3822-3834.
22 CAI X, LIANG C, ZHANG M, et al. N6-methyladenosine modification and metabolic reprogramming of digestive system malignancies[J]. Cancer Lett, 2022, 544: 215815.
Outlines

/